The data are in – so will Gilead’s Trodelvy achieve its potential?
pharmaphorum
MARCH 8, 2022
The company didn’t conduct a conference call to discuss the findings, but took the unusual step of publishing a frequency asked questions (FAQ) document on the study, headlined with a non-committal statement about whether the data were “clinically meaningful.” The company said it “remains confident in that goal.”
52 
Let's personalize your content